The mitotic spindle checkpoint (metaphase checkpoint) is a cell cycle signaling pathway that blocks the division of the chromosomes until they are aligned on the mitotic spindle. In many cancer cells this checkpoint is partially defective leading to the generation of cancers with abnormal numbers of chromosomes. Defective cell cycle checkpoints are potential targets for development of anti-cancer drugs. The mitotic spindle checkpoint is activated in cells treated with anti-tubulin cancer drugs such as taxol and vinblastine. In theory, cancer cells may be preferably more sensitive because their spindle checkpoint systems are partially defective. Drugs that target the spindle checkpoint may be potent anti-cancer agents either alone or in combination with anti-tubulin drugs. A screening assay for small molecule drugs that inactivate the spindle checkpoint is described.

Patents
Please contact the IPMO office for patent information